

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Trientine (Clovique, Syprine)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Clovique (trientine) – generic Syprine (trientine)	May be subject to quantity limit for Medicaid plans

APPROVAL CRITERIA

Requests for trientine (Clovique, Syprine) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Wilson’s Disease as confirmed by **two** of the following (AASLD 2008):
 - A. Serum ceruloplasmin less than 20 mg/dL;
 - B. Presence of Kayser-Fleischer rings;
 - C. 24-hour urinary copper is greater than 40 µg/day;
 - D. Liver biopsy findings consistent with Wilson’s Disease;
 - E. Genetic testing findings consistent with Wilson’s Disease.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 20, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Committee on Drugs, American Academy of Pediatrics. Treatment guidelines for lead exposure in children. *Pediatrics*. 1995; 96:155-60.
6. Pearle MS, Goldfarb DS, Assimos DG, et. al. American Urological Association. Medical management of kidney stones: AUA guideline. *J Urol*. 2014;192(2):316-24. Available from: <https://www.auanet.org/education/guidelines/management-kidney-stones.cfm>. Accessed on: September 19, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

7. Qaseem A, Dallas P, Forcica MA, et al. Dietary and Pharmacologic Management to Prevent Recurrent Nephrolithiasis in Adults: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med.* 2014; 161:659-667. Available from: <https://www.acponline.org/clinical-information/guidelines>. Accessed on: September 19, 2018.
8. Roberts EA, Schilsky ML. AASLD Practice Guidelines: Diagnosis and treatment of Wilson disease: an update. *Hepatology.* 2008;47(6):2089-111. Available from: http://www.aasld.org/sites/default/files/guideline_documents/Wilson%20Disease2009.pdf. Accessed on: September 19, 2018.
9. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken).* 2016; 68(1):1-25. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/full>. Accessed on: September 19, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.